Abstract: A process for hydrogenating a sample in a pressure range below supercritical pressure values includes supplying at least a solvent of the sample to be hydrogenated by a feed pump with a constant volume rate into a flow path to create a base solution; adding the sample being dissolved into the flow path; feeding hydrogen into the flow path through a valve configured to transmit hydrogen only into a single direction; leading the dissolved sample in the presence of a catalyst through a hydrogenation reactor, where the reactor is inserted into a section of the flow path located after the hydrogen feeding position; maintaining the pressure of the reaction in a given pressure range by element of a pressure-adjusting unit, and collecting a hydrogenate formed within the hydrogenation reactor in a product receptacle connected to the end of the flow path.

Abstract: A laboratory scale continuous flow hydrogenation apparatus (100) includes a reservoir (104), a feed pump (102), a mixing element (108) with two inlets and an outlet, a hydrogenation reactor (110) and a pressure-adjusting unit (112), all connected into a flow path. A hydrogen source (126) and a one-way valve (120) are arranged between the hydrogen source (126) and the second inlet of the mixing element (108). The feed pump (102) can provide a constant volume rate. The reservoir (104) contains at least a solvent base solution of the sample to be hydrogenated. The hydrogenation reactor (110) connects into the flow path by detachable connections and is formed as a replaceable cartridge containing a packing which increases the flow resistance and facilitates mixing. The pressure-adjusting unit (112) connects into the flow path after the hydrogenation reactor (110) and is provided with a regulation controlled electrically.

Abstract: The invention relates to (−)-5,6-dihydro-5-(1-piperidinyl)-methyl-3-(3-pyridyl)-4H-1,2,4-oxadiazine to the therapeutical use thereof and to phamaceutical compositions containing the compounds as active ingredient.